Online Exclusive Article

Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia

Julie Feurtado

Robert J. Kreitman

hairy cell leukemia, moxetumomab pasudotox, novel therapies, immunoconjugates
CJON 2019, 23(3), E52-E59. DOI: 10.1188/19.CJON.E52-E59

Background: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited.

Objectives: This article describes clinical guidelines for the administration of moxetumomab pasudotox to patients with R/R HCL and presents related case studies.

Methods: A limited review of the literature on HCL was undertaken.

Findings: Nursing care of patients prescribed moxetumomab pasudotox includes monitoring clinical and laboratory parameters, managing side effects, being aware of signs of serious side effects, and maintaining patient hydration during administration.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.